Ainos, Inc. $AIMD

What the company doesAI summary of filing

Ainos, Inc. is a company developing artificial intelligence–based scent digitization technology and immune therapeutics. The company's primary focus is commercializing AI Nose, an AI-powered electronic olfaction system that digitizes scent and volatile organic compound signals into machine-readable data for applications in healthcare point-of-care testing and industrial environments including semiconductor manufacturing and smart manufacturing. The company generates revenue through hardware sales and subscription-based services for the AI Nose platform, and has secured an initial commercial deployment under a multi-year subscription agreement with a semiconductor company as of 2025. The company also continues to develop VELDONA®, a low-dose oral interferon platform targeting rare, autoimmune, and infectious disease indications, and has commercialized VELDONA® pet supplements in Taiwan, while remaining in the clinical development stage for its human drug candidates. [10-K 2026-03-30]

Segments: AI Nose platform (industrial and healthcare applications), Point-of-Care Testing (POCT), VELDONA® (low-dose oral interferon), VELDONA® Pet supplements